Follicular lymphoma Clinical Trials
Recruiting follicular lymphoma studies with sites across the US, sourced from ClinicalTrials.gov and refreshed daily. Free to join — find one near you below.
Clinical trials study new ways to prevent, detect, or treat follicular lymphoma. Joining one can give you access to investigational treatments and close monitoring by a specialist research team — at no cost — while helping advance care for others. Below are recruiting follicular lymphoma studies with sites across the US; use the location tools to find ones near you.
What to expect
- Screening first. The study team reviews your eligibility before anything else — there's no obligation to continue.
- Informed consent. You'll get a full explanation of the study, its potential risks and benefits, and can withdraw at any time.
- No cost to you. Study visits, tests, and the investigational treatment are covered; many studies reimburse travel.
Recruiting follicular lymphoma trials
A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
Evaluation of Skin Tests in Biotherapy Allergies
Pomalidomide Plus Anti-CD20 Antibody and Prednisone in Frontline Indolent B-Cell Lymphoma
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
A Exploratory Study on Untreated Follicular Lymphoma With Orelabrutinib, Tafasitamab, and Lenalidomide
Mosunetuzumab and Zeprumetostat in Treating Patients With Follicular Lymphoma
Zanubrutinib, Obinutuzumab Combined With Lenalidomide (ZGR) for the Treatment of Untreated Follicular Lymphoma
Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma
A Phase 2, Multicenter, Open-Label Trial to Evaluate Efficacy and Safety of Subcutaneous (SC) Mosunetuzumab in Previously Untreated Low Tumor Burden Follicular Lymphoma (LTB-FL).
Odronextamab in Low Tumor Volume Advanced FL
HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
Fixed-Duration Zanubrutinib, Bendamustine, and Obinutuzumab (ZBG) in Treatment-Naïve Advanced Stage Follicular Lymphoma
JWCAR239 in Patients With B Cell Non-Hodgkin Lymphoma
A Study of Reduced Dose Radiation Therapy for People With B-Cell Lymphomas
Combating Cancer-Related Fatigue: A Personalized Supportive Care Program
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Zanubrutinib Plus GCVP (Obinutuzumab, Cyclophosphamide, Vindesine, Prednisolone) in Previously Untreated Follicular Lymphoma
Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular Lymphoma
64Cu-LLP2A for Imaging Hematologic Malignancies
Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
Axicabtagene Ciloleucel Injection in Patients With Relapsed/Refractory Follicular Lymphoma
LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
A Study to Patients With Relapsed/Refractory Follicular Lymphoma Treated With Liso-cel (Lisocabtagene Maraleucel) in the Post Marketing Setting
Epco, Zanu, Ritux for R/R FL or MZL
CD70-targeted immunoPET Imaging of Malignant Cancers
Radiotherapy Followed by Tiselizumab Combined With RCHOP in Previously Untreated Bulky Follicular Lymphoma
Zanubrutinib, Obinutuzumab and Lenalidomide (ZGR) in High-risk Treatment-naive Patients with Follicular Lymphoma (FL)
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
SynKIR-310 for Relapsed/Refractory B-NHL
Assessing the Experience of Patients Undergoing Follicular Lymphoma Clinical Research
CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas
Study With Mosunetuzumab and Zanubrutinib in R/R Follicular Lymphoma Patients
Prospective Analysis of Circulating Nucleosomes in Patients Receiving a First Line Treatment for a Non-Hodgkin Lymphoma
Emapalumab Prevention of CAR-T Cell Associated Toxicities
Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5
A Phase II Study of SHR2554 in Patients With Relapsed or Refractory Follicular Lymphoma
Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas
Zanubrutinib in Combination With Obinutuzumab (ZO) for Newly Diagnosed Follicular Lymphoma
AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma
Relmacabtagene Autoleucel in Hematologic Malignancies
Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi
Effectiveness and Safety of Tisagenlecleucel Therapy in Brazilian Patients With B-lymphocyte Malignancies
Lenalidomide Combined With G-CHOP in the Treatment of Newly Diagnosed DLBCL With FL
Chidamide Combined With Linperlisibon for the Treatment of Refractory/Relapsed Follicular Lymphoma
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
(CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL)
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
Multilayer Biological Characterization of Advanced Follicular Lymphoma: a Translational Study From FIL_FOLL12 Trial
IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
Epcoritamab and Rituximab for First-line Follicular Lymphoma
A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL
Allo HSCT Using RIC and PTCy for Hematological Diseases
A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)
Study of SGR-1505 in Mature B-Cell Neoplasms
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
Follicular lymphoma clinical trials — common questions
Are follicular lymphoma clinical trials free to join?
Yes. Participating in a follicular lymphoma clinical trial is free — study-related visits, tests, and the investigational treatment are provided at no cost to you. Many studies also reimburse travel and time. You never pay to take part.
Who can join a follicular lymphoma clinical trial?
Each follicular lymphoma study sets its own eligibility criteria — typically based on age, medical history, current treatments, and overall health. Every trial listed here shows its criteria, and the study team confirms your eligibility before enrollment. You can review and apply to any that look like a fit.
How do I find a follicular lymphoma trial near me?
Use the location controls above. We'll show recruiting follicular lymphoma trials with sites near you, sorted by distance. You can widen the radius or share your exact location for the closest matches.
How many follicular lymphoma trials are recruiting right now?
We're currently tracking roughly 55 recruiting follicular lymphoma trials with US sites, sourced from ClinicalTrials.gov and refreshed daily.
Looking for a specific location? Browse trials by city and state.